Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

Subgroup analyses of a randomized global phase II study of axitinib showed objective response rate of 66% and median progression‐free survival of 27.6 months in treatment‐naïve Japanese patients with metastatic renal cell carcinoma (RCC). This analysis evaluated overall survival (OS) and safety in 4...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Oya, Mototsugu, Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Uemura, Hirotsugu
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5480076/
https://ncbi.nlm.nih.gov/pubmed/28267243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados